Angiotensin-II down-regulates cardiac natriuretic peptide receptor-A mediated anti-hypertrophic signaling in experimental rat hearts

Indian Journal of Experimental Biology

Volumn 51, Issue 1, 2013, Pages 48-55

  Gop, Venkatachalam ^a   Parthasarathy, Arumugam ^a   Umadevi, Subramanian ^a   Vellaichamy, Elangovan ^a  

^a UNIVERSITY OF MADRAS   (India)

Author keywords

Angiotensin II; Atrial natriuretic peptide; Guanylyl cyclase activity; Left ventricular hypertrophy; Natriuretic peptide receptor A

Indexed keywords

ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; ATRIAL NATRIURETIC FACTOR RECEPTOR; GUANYLATE CYCLASE; NATRIURETIC PEPTIDE RECEPTOR A;

ANIMAL; ARTICLE; BIOLOGICAL MODEL; CHEMISTRY; DOWN REGULATION; GENE EXPRESSION REGULATION; HEART; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE; HEART VENTRICLE; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; RAT; SIGNAL TRANSDUCTION; WISTAR RAT;

ANGIOTENSIN II; ANIMALS; ATRIAL NATRIURETIC FACTOR; DOWN-REGULATION; GENE EXPRESSION REGULATION; GUANYLATE CYCLASE; HEART; HEART VENTRICLES; HYPERTROPHY, LEFT VENTRICULAR; MALE; MODELS, BIOLOGICAL; MYOCARDIUM; RATS; RATS, WISTAR; RECEPTORS, ATRIAL NATRIURETIC FACTOR; SIGNAL TRANSDUCTION;

RATTUS; RATTUS NORVEGICUS;

EID: 84871815998     PISSN: 00195189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Raskin A M, Hoshijima M, Swanson E, McCulloch A D & Omens J H, Hypertrophic gene expression induced by chronic stretch of excised mouse heart muscle, Mol Cell Biomech, 6 (2009)145.
2. Tokola H, Hautala N, Marttila M, Magga J, Pikkarainen S, Kerkelä R, Vuolteenaho O & Ruskoaho H, Mechanical loadinduced alterations in B-type natriuretic peptide gene expression, Can J Physiol Pharmacol, 79 (2001) 646.
3. Potter L R, Guanylyl cyclase structure, function and regulation, Cell Signal, 23 (2011) 1921.
4. Pandey K N, Biology of natriuretic peptides and their receptors, Peptides, 26 (2005) 901.
5. Franco V, Chen Y F, Oparil S, Feng J A, Wang D, Hage F, Perry G & Kishimoto, T, Atrial natriuretic peptide dosedependently inhibits pressure overload-induced cardiac remodelling, Hypertension, 44 (2004) 746.
6. Kishimoto I, Tokudome T, Horio T, Garbers D L, Nakao K & Kangawa K, Natriuretic peptide signaling via guanylyl cyclase (GC)-A: An endogenous protective mechanism of the heart, Curr Cardiol Rev, 5 (2009) 45.
7. Zahabi A, Picard S, Fortin N, Reudelhuber T L & Deschepper C F, Expression of constitutively active guanylate cyclase in cardiomyocytes inhibits the hypertrophic effects of isoproterenol and aortic constriction on mouse hearts, J Biol Chem, 278 (2003) 47694.
8. Hayashi D, Kudoh S, Shiojima I, Zou Y, Harada K, Shimoyama M, Imai Y, Monzen K, Yamazaki T, Yazaki Y, Nagai R & Komuro I, Atrial natriuretic peptide inhibits cardiomyocyte hypertrophy through mitogen-activated protein kinase phosphatase-1, Biochem Biophys Res Commun, 322 (2004) 310.
9. Kapoun A M, Liang F, O'Young G, Damm D L, Quon D, White R T, Munson K, Lam A, Schreiner G F & Protter A A, B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation, Circ Res, 94 (2004) 453.
10. Vellaichamy E, Khurana ML, Fink J & Pandey K N, Involvement of the NF-kappa B/matrix metalloproteinase pathway in cardiac fibrosis of mice lacking guanylyl cyclase/natriuretic peptide receptor A, J Biol Chem, 280 (2005) 19230.
11. Oliver P M, Fox J E, Kim R, Rockman H A, Kim H S, Reddick R L, Pandey K N, Milgram S L, Smithies O & Maeda N, Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A, Proc Natl Acad Sci U S A, 94 (1997) 14730.
12. Ruskoaho H, Cardiac hormones as diagnostic tools in heart failure, Endocr Rev, 24 (2003) 341.
13. Dickey D M, Dries D L, Margulies K B & Potter L R, Guanylyl cyclase (GC)-A and GC-B activities in ventricles and cardiomyocytes from failed and non-failed human hearts: GC-A is inactive in the failed cardiomyocyte, J Mol Cell Cardiol, 52 (2012) 727.
14. Kinoshita H, Kuwahara K, Nishida M, Jian Z, Rong X, Kiyonaka S, Kuwabara Y, Kurose H, Inoue R, Mori Y, Li Y, Nakagawa Y, Usami S, Fujiwara M, Yamada Y, Minami T, UeshimaK & Nakao K, Inhibition of TRPC6 channel activity contributes to the antihypertrophic effects of natriuretic peptides-guanylyl cyclase-A signaling in the heart, Circ Res, 106 (2010) 1849.
15. Mehta P K & Griendling K K, Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system, Am J Physiol Cell Physiol, 292 (2007) C82.
16. Cooper S A, Whaley-Connell A, Habibi J, Wei Y, Lastra G, Manrique C, Stas S & Sowers J R. Renin-angiotensinaldosterone system and oxidative stress in cardiovascular insulin resistance, Am J Physiol Heart Circ Physiol, 293 (2007) H2009.
17. De Rosa ML, Cardace P, Rossi M, Baiano A, de Cristofaro A. Comparative effects of chronic ACE inhibition and AT1 receptor blocked losartan on cardiac hypertrophy and renal function in hypertensive patients, J Hum Hypertens, 16 (2002) 133.
18. Suzuki H, Kanno Y, Kaneko K, Kaneko M, Kotaki S, Mimura T, Takane H. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy, Ther Apher Dial, 8 (2004) 320.
19. Arise K K & Pandey K N, Inhibition and down-regulation of gene transcription and guanylyl cyclase activity of NPRA by angiotensin II involving protein kinase C, Biochem Biophys Res Commun, 349 (2006) 131.
20. Bottari S P, King I N, Reichlin S, Dahlstroem I, Lydon N & deGasparo M, The angiotensin AT2 receptor stimulates protein tyrosine phosphatase activity and mediates inhibition of particulate guanylate cyclase, Biochem Biophys Res Commun, 183 (1992) 206.
21. Schiffrin E L, Turgeon A, Tremblay J & Deslongchamps M, Effects of ANP, angiotensin, vasopressin, and endothelin on ANP receptors in cultured rat vascular smooth muscle cells, Am J Physiol, 260 (1991) H58.
22. Schultz Jel J, Witt SA, Glascock BJ, Nieman ML, Reiser PJ, Nix SL, Kimball TR, Doetschman T, TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II, J Clin Invest, 109(6) (2002) 787.
23. Bouzegrhane F & Thibault G, Is angiotensin II a proliferative factor of cardiac fibroblasts? Cardiovasc Res, 53 (2002) 304.
24. Haddad G E, Blackwell K & Bikhazi A, Regulation of insulin-like growth factor-1 by the renin-angiotensin system during regression of cardiac eccentric hypertrophy through angiotensin-converting enzyme inhibitor and AT1 antagonist, Can J Physiol Pharmacol, 81 (2003) 142.
25. Vellaichamy E, Zhao D, Somanna N & Pandey K N, Genetic disruption of guanylyl cyclase/natriuretic peptide receptor-A upregulates ACE and AT1 receptor gene expression and signaling: Role in cardiac hypertrophy, Physiol Genomics, 31 (2007) 193.
26. Lee J, Kim S, Jung M, Oh Y & Kim SW, Altered expression of vascular natriuretic peptide receptors in experimental hypertensive rats, Clin Exp Pharmacol Physiol, 29 (2002): 299.
27. Dickey DM, Flora DR, Bryan PM, Xu X, Chen Y & Potter LR, Differential regulation of membrane guanylyl cyclases in congestive heart failure: natriuretic peptide receptor (NPR)-B, Not NPR-A, is the predominant natriuretic peptide receptor in the failing heart, Endocrinology, 148 (2007) 3518.
28. Li Y, Kishimoto I, Saito Y, Harada M, Kuwahara K, Izumi T, Takahashi N, Kawakami R, Tanimoto K, Nakagawa Y, Nakanishi M, Adachi Y, Garbers D L, FukamizuA & Nakao K, Guanylyl cyclase-A inhibits angiotensin II type 1A receptor-mediated cardiac remodeling, an endogenous protective mechanism in the heart, Circulation,106 (2002) 1722.
29. Chen S, Su J, Wu K, Hu W & Gardner D G, Chen D, Early captopril treatment prevents hypertrophy dependent gene expression in hearts of SHR, Am J Physiol, 274 (1998) R1511.
30. Wiesner R J, Ehmke H, Faulhaber J, Zak R & Rüegg J C, Dissociation of left ventricular hypertrophy, beta-myosin heavy chain gene expression, and myosin isoform switch in rats after ascending aortic stenosis, Circulation, 95 (1997) 1253.
31. Tang T, Lai N C, Hammond H K, Roth D M, Yang Y, Guo T & Gao M H, Adenylyl cyclase 6 deletion reduces left ventricular hypertrophy, dilation, dysfunction, and fibrosis in pressure-overloaded female mice, J Am Coll Cardiol, 55 (2010) 1476.
32. Xu J, Lin S C, Chen J, Miao Y, Taffet G E, Entman M L & Wang Y, CCR2 mediates the uptake of bone marrow-derived fibroblast precursors in angiotensin II-induced cardiac fibrosis, Am J Physiol Heart Circ Physiol, 302 (2011) H538.
33. Ryan M J, Didion S P, Mathur S, Faraci F M & Sigmund C D, Angiotensin II-induced vascular dysfunction is mediated by the AT1A receptor in mice, Hypertension, 43 (2004) 1074.
34. Westendorp B, Schoemaker R G, Buikema H, Boomsma F, van Veldhuisen D J & vanGilst W H, Progressive left ventricular hypertrophy after withdrawal of long-term ACE inhibition following experimental myocardial infarction, Eur J Heart Fail, 8 (2006) 122.
35. Sukumaran V, Watanabe K, Veeraveedu P T, Thandavarayan R A, Gurusamy N, Ma M, Yamaguchi K, Suzuki K, Kodama M, Aizawa Y & Telmisartan, An angiotensin-II receptor blocker ameliorates cardiac remodeling in rats with dilated cardiomyopathy, Hypertens Res, 33 (2010) 695.